Status:
COMPLETED
Single or Repeat Dose of G03-52-01 in Adult Subjects
Lead Sponsor:
Alachua Government Services, Inc.
Collaborating Sponsors:
United States Department of Defense
Conditions:
Healthy
Botulinum Toxin
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
A Phase 2, randomized, double-blind, placebo-controlled single or repeat dose trial
Detailed Description
A Phase 2, multicenter, randomized, double-blinded, placebo-controlled study to evaluate a single (100 mg) or repeat dose (50 mg and 100 mg) of G03-52-01 administered by IM injection(s) in adult subje...
Eligibility Criteria
Inclusion
- Informed consent understood and signed prior to screening procedures.
- Assessed by the Investigator to be a healthy male or healthy, non-pregnant, non-lactating female between the ages of 18 and 65 inclusive on the day of dosing.
- Able and willing to comply and be available for all protocol procedures and follow-up for the duration of the study.
- Body Mass Index (BMI) of ≥18.5 and ≤35 kg/m2.
- Females of child-bearing potential must have a negative serum pregnancy test at screening and negative urine pregnancy test on Day 1 prior to dosing.
- \- A woman is considered of childbearing potential unless post-menopausal (≥ 1 year without menses) or surgically sterilized via bilateral oophorectomy, or hysterectomy or bilateral tubal ligation.
- If the subject is female and of childbearing potential, she agrees to practice abstinence from sexual intercourse with men or use medically effective contraception (methods with a failure rate of \< 1% per year when used consistently and correctly) during participation in the study. Acceptable methods include:
- Hormonal contraception including implants, injections or oral
- Two barrier methods, e.g., condom and cervical cap (with spermicide) or diaphragm (with spermicide)
- Intrauterine device (IUD) or intrauterine system
- Screening clinical laboratory results within normal ranges or are no greater than a Grade 1 and deemed not clinically significant by Medical Monitor (MM) and Principal Investigator (PI). Any subjects with results that are Grade 2 or above according to Appendix B will be excluded.
- \- Laboratory values that are outside the range of eligibility but are thought to be due to an acute condition or due to laboratory error may be repeated once.
- The urine drug screen is negative.
- For Cohorts 1-3, if a subject has a positive urine drug screen that the PI believes is caused by a currently prescribed medication, (except for THC), the PI may enroll the subject if they meet all inclusion criteria, and none of the exclusion criteria.
- For Cohort 4, if a subject has a positive urine drug screen that the PI believes is caused by a currently prescribed medication or positive for THC, the PI may enroll the subject if they meet all other inclusion criteria and none of the exclusion criteria.
- Breathalyzer test is negative.
- Available for follow-up for the duration of the study.
- Agrees not to participate in vigorous activity 2 days prior to dosing and 2 days post-dose Day 1 and Day 45 for Cohorts 1-3 and Day 1 for Cohort 4, per Investigator discretion.
Exclusion
- History of a chronic medical condition that would either interfere with the accurate assessment of the objectives of the study or increase the risk profile of the subject.
- \- Chronic medical conditions include but are not limited to diabetes; Asthma requiring use of medication in the year before screening; Autoimmune disorder such as lupus, Wegener's, rheumatoid arthritis, thyroid disease; coronary artery disease; chronic hypertension; History of malignancy except low-grade (squamous and basal cell) skin cancer thought to be cured; chronic renal, hepatic, pulmonary, or endocrine disease (except previous asthma which has required no treatment for the past year).
- Known history of severe allergic reaction of any type to medications, bee stings, food, or environmental factors or hypersensitivity or reaction to immunoglobulins.
- \- Severe allergic reactions are defined as any of the following: anaphylaxis, urticaria, or angioedema.
- Known allergic reactions to any of the study product components present in the formulation or in the processing.
- A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval \>450 milliseconds).
- Clinically significant abnormal electrocardiogram (ECG) at screening.
- \- Clinically significant abnormal ECG results include but are not limited to: complete left or right bundle branch block; other ventricular conduction block except for incomplete RBB; 2nd degree or 3rd degree atrioventricular (AV) block; sustained ventricular arrhythmia; sustained atrial arrhythmia; two Premature Ventricular Contractions in a row; pattern of ST elevation felt consistent with cardiac ischemia; or any condition deemed clinically significant by a study investigator.
- Positive serology results for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) antibodies.
- Febrile illness with temperature ≥38°C within 7 days of dosing. Subjects with acute febrile illness within 7 days of dosing may be rescreened no earlier than 7 days following resolution of symptoms.
- Female subjects that are pregnant or breastfeeding or intending to become pregnant within the projected duration of the trial starting from the Screening visit until last dose.
- Donation of blood or blood product within 56 days of enrollment.
- Is currently participating or has participated in a study with an investigational product (IP) within 28 days preceding Day 1 (documented receipt of placebo in a previous trial would be permissible for trial eligibility)
- Plans to enroll in another clinical trial that could interfere with safety assessment of the IP at any time during the study period.
- \- Includes trials that have a study intervention such as a drug, biologic, or device only
- Treatment with a mAB within 3 months of Day 1.
- Receipt of antibody (e.g., tetanus immune globulin \[TIG\], varicella zoster immune globulin \[VZIG\], intravenous immunoglobulin \[IVIG\], IM gamma globulin) or blood transfusion within 6 months or within 5 half-lives of the specific product given.
- Reported active drug or alcohol or substance abuse/independence or illicit drug use that, in the opinion of the Investigator, would interfere with adherence to study requirements.
- Use of H1 antihistamines or beta-blockers within 5 days of dosing Day 1 and Day 45 for Cohorts 1-3 and Day 1 for Cohort 4 (PRN use could be allowed with MM approval).
- Use of any prohibited medication within 28 days prior to study entry or planned use during the study period.
- \- Note: Prohibited medications include immunosuppressives (except nonsteroidal anti-inflammatory drugs \[NSAIDs\]); immune modulators; oral corticosteroids (topical/intranasal steroids are acceptable); anti-neoplastic agents.
- Previous exposure to botulinum toxin, receipt of antibodies against botulinum toxin, or previous treatment with equine antitoxin.
- Any previous injection or any planned injection within 4 months after enrollment of botulinum toxin for cosmetic reasons, spastic dysphonia, torticollis, or any other reason.
- Any illness or condition that in the judgment of the Investigator may affect the safety of the subject or the evaluation of any study endpoint.
- Is a study site employee, staff, or close relative as defined.
- PIs and Sub-Investigators
- Staff who are supervised by the PI, Sub-Investigators
- Member of the team conducting this clinical trial
- Children, spouse, partners, siblings, and parents of site staff
Key Trial Info
Start Date :
June 29 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 4 2025
Estimated Enrollment :
625 Patients enrolled
Trial Details
Trial ID
NCT05348993
Start Date
June 29 2022
End Date
February 4 2025
Last Update
February 11 2025
Active Locations (15)
Enter a location and click search to find clinical trials sorted by distance.
1
AMR Mobile
Mobile, Alabama, United States, 36608
2
AMR Tempe
Tempe, Arizona, United States, 85281
3
AMR Fort Myers
Fort Myers, Florida, United States, 33912
4
AMR Miami
Miami, Florida, United States, 33134